NCT03725761View on ClinicalTrials.gov

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 24, 2018

Primary Completion Date

April 18, 2024

Study Completion Date

September 30, 2027

Conditions
Prostate Cancer
Interventions
DRUG

Sacituzumab Govitecan

Sacituzumab Govitecan is a novel Antibody Drug Conjugate (ADC) based on a humanized anti-Trop-2 antibody (hRS7) conjugated to SN-38 payload.

Trial Locations (3)

10065

Memorial Sloan-Kettering Cancer Center, New York

Weill Cornell Medical College, New York

53792

University of Wisconsin Carbone Cancer Center, Madison

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Gilead Sciences

INDUSTRY

lead

University of Wisconsin, Madison

OTHER

NCT03725761 - Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy | Biotech Hunter | Biotech Hunter